Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases
Arciero C, Salem R, Lacy J, Sigurdson E, Hoffman J, Watson J, Joseph N, Cooper H, Meropol N, Burtness B. Hepatic metastasectomy following FOLFOX therapy in patients with colorectal metastases. Journal Of Clinical Oncology 2006, 24: 13523-13523. DOI: 10.1200/jco.2006.24.18_suppl.13523.Peer-Reviewed Original ResearchHepatic metastasectomyPathologic complete responseFOLFOX chemotherapySynchronous metastasesAdverse prognostic featuresHigher lesion numberMedian age 55Multiple wedge resectionsTumor size 1Portal lymph nodesMetastatic colon cancerResidual cancer cellsCurative intentMedian followColorectal metastasesFOLFOX therapyOverall survivalOxaliplatin chemotherapyPathologic responseRadiographic responseResidual cancerSystemic therapyWedge resectionComplete resectionComplete responsePostchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer
Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer. The Cancer Journal 2006, 12: 212-221. PMID: 16803680, DOI: 10.1097/00130404-200605000-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDocetaxelDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMagnetic Resonance ImagingMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm, ResidualPrognosisSurvival RateTaxoidsTreatment OutcomeConceptsAdvanced breast cancerPathologic complete responseMagnetic resonance imagingComplete responseBreast cancerResonance imagingNeoadjuvant chemotherapyPreoperative magnetic resonance imagingResidual invasive carcinomaBreast magnetic resonance imagingResidual tumor sizeSerial magnetic resonanceBreast magnetic resonanceMagnetic resonanceEligible patientsPrimary chemotherapyNeoadjuvant therapyResidual cancerAxillary lesionsPathologic evaluationStable patientsAdditional patientsPosttreatment examinationResidual diseaseTumor size